PPCB Latest Press Releases

-- October 22, 2026 --

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans Globe Newswire 8:30 AM

-- October 16, 2026 --

Propanc Biopharma's Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells Globe Newswire 8:36 AM

-- October 14, 2026 --

Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer Globe Newswire 8:30 AM

-- October 7, 2026 --

Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines' Daraxonrasib Globe Newswire 8:30 AM

-- September 29, 2026 --

Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results Globe Newswire 8:30 AM

-- September 22, 2026 --

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015 Globe Newswire 8:30 AM

-- September 16, 2026 --

Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc. Globe Newswire 8:30 AM

-- September 9, 2026 --

Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027 Globe Newswire 8:30 AM

-- August 27, 2026 --

Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit Globe Newswire 8:30 AM

-- August 18, 2026 --

Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP Globe Newswire 8:30 AM

-- August 12, 2026 --

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers Globe Newswire 8:30 AM

-- August 6, 2026 --

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models Globe Newswire 8:30 AM

-- August 5, 2026 --

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program Globe Newswire 8:30 AM

-- July 21, 2026 --

Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal Globe Newswire 8:30 AM

-- July 7, 2026 --

Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd Globe Newswire 8:30 AM

-- July 2, 2026 --

Propanc Biopharma Initiates $5.0 Million Share Repurchase Program Globe Newswire 8:30 AM

-- June 16, 2026 --

Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study Globe Newswire 8:45 AM

-- June 11, 2026 --

ShareStructure.io Announces Investor Education Platform on Public Company Financing Activity. Globe Newswire 10:44 AM

Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program Globe Newswire 8:30 AM

-- June 2, 2026 --

Propanc Biopharma's CEO Attends Keynote Address, "Rejuvenation and Health: Science for an Ageing Society," at the University of Granada, Spain Globe Newswire 5:30 AM

Market Data Delayed 15 Minutes